Amgen and Arrakis Therapeutics Announce Multi-Target …
THOUSAND OAKS, Calif. and WALTHAM, Mass., Jan. 11, 2022 – Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a range of difficult-to-drug targets in multiple therapeutic areas.
Arrakis - Arrakis Therapeutics
EXPLORE WHAT'S NEW. We are pioneering a new world of rSM medicines, ourselves and with partners. Amgen and Arrakis Therapeutics Announce Multi-Target Collaboration to Identify Novel RNA Degrader Small Molecule Therapeutics. JOIN THE EXPEDITION. We are on a mission that takes fearlessness and resilience to pioneer new science, but we also make ...
News Releases - Arrakis Therapeutics
Jan 10, 2022 · Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche for Multi-Target Program Utilizing RNA-Targeted Small Molecule Drug Discovery Platform. February 05, 2020. Arrakis Therapeutics Appoints Jacques Dumas, Ph.D., as Senior Vice President, Drug Discovery. November 21, 2019.
AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI …
Jan 11, 2022 · Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas.
AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI …
Jan 11, 2022 · Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life science ...
Amgen partners with Arrakis to develop drugs aimed at RNA
Jan 11, 2022 · Amgen will team with Arrakis Therapeutics to develop oral drugs that target and destroy RNA, announcing a deal Tuesday that will pay the Waltham, Massachusetts-based biotech $75 million in cash.
Amid a pandemic, Roche bets $190M on Arrakis and drugging RNA
Apr 8, 2020 · Arrakis now has a pipeline that includes potential drugs for cancer, neurological diseases, rare disorders, and dyslipidemia. The Roche deal is the company's first, but it marks one of the largest bets on RNA-targeting small molecule …
Arrakis Therapeutics Appoints James Mutamba, PhD, as Chief …
Dec 6, 2021 · Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas.
Amgen taps Waltham biotech Arrakis Therapeutics for RNA …
Jan 11, 2022 · Arrakis and Amgen will work together to create small molecules that can bind to and degrade certain disease-causing RNAs. For Amgen, the deal marks an expansion.
Arrakis Therapeutics Enters Strategic Collaboration and License ...
Apr 8, 2020 · Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas.
- Some results have been removed